PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

June 30, 2015

Conditions
Diabetic Retinopathy
Interventions
DEVICE

PASCAL laser

A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.

DEVICE

Conventional laser

Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.

All Listed Sponsors
lead

Kocatepe University

OTHER

NCT02645383 - PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System | Biotech Hunter | Biotech Hunter